You aren't wrong about the gains over the last ~2 years, assuming you were risky enough to buy a company that stopped SEC reporting and only gave 1-2 updates a year, that is. Considering back when several of us first bought here before that, the pps was routinely in the .15 to .20 range, so it's not much different today.
Market Cap: as mentioned yesterday, .25 is the high end IMO for the time being, and it's back down to ~9m or .20 PPS today. 45m OS is higher, but I'd be more cautious if the MC was 2-3x right now, as then everything potentially upcoming would seem baked-in. ~10m MC for a small bio company is pretty typical and many others have zero revenue, so revenues are typically the last thing that's looked at for bio companies. I would agree that the MC is slightly higher valued currently, but this is just based on the fact they haven't SEC reported for 3-4 years. Assuming they begin to report again this year, this should give them legitimacy as an actual company, which I'd say easily justifies the current 10m MC, and perhaps even bumps it up by 10-25%. And on top of that, assuming all of their numbers have been correct the last ~2 years, and they continue to increase revenue with perhaps achieving positive bottom line as well, this makes them stand above the other bios in terms of potential and a consistent MC of ~20m does not seem out of the question by this time next year.
So all that said, that's what I mean by about to pay off. Granted, a lot has to happen, so still more risky than other stocks, but the potential is there to be much bigger.
